Nombre del producto:4-(2-CYANOPROPAN-2-YLAMINO)-2-FLUORO-N-METHYLBENZAMIDE

IUPAC Name:4-[(1-cyano-1-methylethyl)amino]-2-fluoro-N-methylbenzamide

CAS:915087-32-0
Fórmula molecular:C12H14FN3O
Pureza:95%+
Número de catálogo:CM329948
Peso molecular:235.26

Unidad de embalaje Stock disponible Precio($) Cantidad
CM329948-100mg in stock ȷɐȷ
CM329948-250mg in stock Ƌɐȷ
CM329948-1g in stock ɐȌſ
CM329948-5g 1-2 Weeks ȷDzȦȷ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :915087-32-0
Fórmula molecular:C12H14FN3O
Punto de fusión:-
Código de sonrisas:O=C(NC)C1=CC=C(NC(C)(C#N)C)C=C1F
Densidad:
Número de catálogo:CM329948
Peso molecular:235.26
Punto de ebullición:
Nº Mdl:
Almacenamiento:

Column Infos

Enzalutamide
Aug. 23, 2023, FDA grants priority review for XTANDI(enzalutamide) in non-metastatic castration-sensitive prostate cancer with high-risk biochemical recurrence.
XTANDI (enzalutamide) is an androgen receptor signaling inhibitor. Androgen receptor inhibitors interfere with the connection between androgens and androgen receptors. This can help slow cancer cell growth.XTANDI is currently approved for one or more of these indications in more than 100 countries, including in the U.S., European Union and Japan. Over one million patients have been treated with XTANDI globally.